Fusion Antibodies is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Using latest genomic mining software a pipeline of targets (mediators in disease development) have been discovered and are presently being evaluated for therapeutic and diagnostic suitability. Our team of researchers stem from haemtology, clinical oncology, pharmacology, immunology and molecular biotechnology. The use of an integrated and multi disciplinary team approach to drug discovery enables Fusion Antibodies to rapidly design and develop test reagents for project evaluation using our high throughput recombinant protein platform.

Research Focus
The R&D is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials. 




read more>>